Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clacier
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Clacier is an ophthalmic nanoemulsion containing 0.05% Cyclosporine. It functions as a calcineurin inhibitor and an immunosuppressant. Primarily, it is used to enhance tear production in patients suffering from dry eye syndrome (keratoconjunctivitis sicca) due to ocular inflammation. Beyond its ophthalmic application, Clacier, through its active ingredient Cyclosporine, exerts broader immunosuppressive effects, making it valuable in preventing organ transplant rejection and managing various autoimmune disorders.
- Brand names
- Clacier
02
Targets
CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on Clacier.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clacier.